CM Life Sciences II, a special-purpose acquisitions company (SPAC) focused on life sciences, announced on 22 March it has signed an agreement to merge with Boulder, CO-based SomaLogic, Inc., a proteomics technology platform company.
CM Life Sciences, led by affiliates of institutional investors Casdin Capital LLC and Corvex Management, could combine with SomaLogic, a deal that is estimated to be worth around $1.25bn, according...